Literature DB >> 1994912

Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs.

B Haraoui1, J P Pelletier, J M Cloutier, M P Faure, J Martel-Pelletier.   

Abstract

We examined the histologic and immunopathologic features of the synovial membrane of 18 patients with rheumatoid arthritis (RA) and 12 patients with osteoarthritis (OA) who had undergone total knee arthroplasty. Patients were classified into 5 groups according to therapeutic regimen and disease: RA treated with nonsteroidal antiinflammatory drugs (NSAIDs), RA treated with NSAIDs and prednisone, RA treated with NSAIDs and methotrexate (MTX), OA treated with analgesics, and OA treated with NSAIDs. There were no significant between-group differences in the percentages or the distribution pattern of the infiltrating T cell subsets (CD4, CD8), HLA-DR, or interleukin-2 receptor-bearing cells. However, inflammatory indices, which included the thickness of the lining cell layer and the density of the mononuclear cell infiltrate, were significantly higher in the RA patients treated with prednisone and those treated with MTX (P less than 0.05). Similarly, fibrosis was markedly reduced in these 2 groups. The RA patients treated with NSAIDs alone and the 2 groups of patients with OA demonstrated similar profiles. These data suggest that prednisone and MTX may inhibit the development of fibrosis without altering the subsets of the inflammatory cell population. This observation raises the possibility that the action of these 2 drugs may be partly mediated by the suppression of inflammatory mediators that are responsible for fibroblast activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1994912     DOI: 10.1002/art.1780340205

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 2.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  Serum and synovial fluid C-reactive protein level variations in dogs with degenerative joint disease and their relationships with physiological parameters.

Authors:  S Boal; L Miguel Carreira
Journal:  Vet Res Commun       Date:  2015-07-16       Impact factor: 2.459

Review 4.  Nonsteroidal anti-inflammatory drugs and chondroprotection. A review of the evidence.

Authors:  P Ghosh
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

5.  The role of synovitis in osteoarthritis.

Authors:  Claire Y J Wenham; Philip G Conaghan
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

Review 6.  Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?

Authors:  P Creamer
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

7.  Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism.

Authors:  Juliane Aline Paupitz; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-03-26       Impact factor: 2.631

8.  Intracapsular pressure and interleukin-1beta cytokine in hips with acetabular dysplasia.

Authors:  Jun Xie; Masatoshi Naito; Akira Maeyama
Journal:  Acta Orthop       Date:  2010-04       Impact factor: 3.717

9.  Detection of tumour necrosis factor alpha and interleukin-1 beta in the rheumatoid osteoarthritic cartilage-pannus junction by immunohistochemical methods.

Authors:  V E Miller; K Rogers; K D Muirden
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

10.  Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs.

Authors:  G W Lu; H W Jun; M T Dzimianski; H C Qiu; J W McCall
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.